Crucell Signs Second Exclusive License Agreement with Talecris Biotherapeutics

22-Dec-2008 - Netherlands

Crucell N.V. announced that it has signed a second exclusive, commercial license agreement with Talecris BioTherapeutics for an undisclosed and specific protein and the exclusive rights to produce that protein using the PER.C6® cell line.

Crucell will receive an upfront payment of $1.5 million following the execution of the agreement and will be eligible for milestone payments of approximately $20 million. Further financial details of the agreement were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances